Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
CKD
Advertisement
Arch Biopartners Expands LSALT Peptide Phase 2 Kidney Injury Trial to U.S.
TORONTO, Canada, August 11, 2026 Arch Biopartners Inc. announced plans to expand its ongoing Phase 2 clinical trial of...
Alebund Pharmaceuticals Gains China NMPA NDA Acceptance
SHANGHAI, August 7, 2026 Alebund Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) has formally accepted for review...
Novo Nordisk Reports ZEUS Phase 3 Results for Ziltivekimab
BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...
Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
Advertisements
Renalytix KidneyIntelX® Delivers Strong Two-Year DKD Outcomes
NEW YORK, June 30, 2026 Renalytix PLC has announced the publication of groundbreaking two-year real-world evidence (RWE) demonstrating that...
Mediar Starts Phase 1 Trial of MTX-439 in CKD
BOSTON, Mass. | June 23, 2026 Mediar Therapeutics has announced that the first cohorts have been dosed in its...
Idorsia’s Aprocitentan Reduces Albuminuria in Resistant Hypertension
ALLSCHWIL, Switzerland, June 1, 2026 Idorsia Ltd announced new Phase 3 PRECISION study analyses showing that aprocitentan, its dual...
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
Advertisement
